膳食纤维与全谷物在糖尿病管理中的作用:系统综述与荟萃分析
该系统综述与荟萃分析纳入2个多国队列共8300名1型或2型糖尿病成人(平均随访8.8年)及42项试验共1789名糖尿病前期、1型或2型糖尿病成人,评估高纤维摄入对死亡率和血糖控制等心血管代谢危险因素的影响。队列数据显示每日膳食纤维摄入35 g相比平均19 g,每1000名参与者研究期间绝对减少14例死亡(95%CI 4-19)。增加纤维摄入可改善糖化血红蛋白、空腹血糖、胰岛素、HOMA IR、血脂、体重、BMI和C反应蛋白等指标。
要点
- 每日纤维摄入35 g相比19 g,每1000名糖尿病成人研究期间减少14例死亡(95%CI 4-19)。
- 增加纤维摄入降低HbA1c(MD -2.00 mmol/mol,95%CI -3.30至-0.71,33项试验)。
- 每日增加纤维15 g或达到35 g可能是糖尿病成人降低早死风险的合理目标。
核心结论
- 高纤维饮食是糖尿病管理的重要组成部分,可改善血糖控制、血脂、体重和炎症指标,并降低早死风险。
- 这些获益不限于特定纤维类型或糖尿病类型,且在不同摄入范围内均可见。
研究设计与样本
- 系统综述与荟萃分析,纳入前瞻性队列研究和对照试验。
- 纳入2个多国队列共8300名1型或2型糖尿病成人,平均随访8.8年。
- 纳入42项试验共1789名糖尿病前期、1型或2型糖尿病成人。
主要发现
- 每日纤维摄入35 g相比平均19 g,每1000名参与者研究期间绝对减少14例死亡(95%CI 4-19),呈明确剂量反应关系。
- 增加纤维摄入降低HbA1c(MD -2.00 mmol/mol,95%CI -3.30至-0.71,33项试验)和空腹血糖(MD -0.56 mmol/L,95%CI -0.73至-0.38,34项试验)。
- 增加纤维摄入降低胰岛素(SMD -2.03,95%CI -2.92至-1.13,19项试验)和HOMA IR(MD -1.24 mg/dL,95%CI -1.72至-0.76,9项试验)。
- 增加纤维摄入降低总胆固醇(MD -0.34 mmol/L,95%CI -0.46至-0.22,27项试验)、LDL胆固醇(MD -0.17 mmol/L,95%CI -0.27至-0.08,21项试验)和甘油三酯(MD -0.16 mmol/L,95%CI -0.23至-0.09,28项试验)。
关键数值与推荐
- 前瞻性队列比较每日膳食纤维摄入35 g与平均19 g,每1000名参与者研究期间绝对减少14例死亡(95%CI 4-19)。
- 试验比较较高纤维摄入与较低纤维饮食,HbA1c平均差异-2.00 mmol/mol(95%CI -3.30至-0.71)。
- 基于 findings,每日增加纤维摄入15 g或达到35 g可能是合理目标。
临床怎么用
- 在糖尿病管理中推荐高纤维饮食以改善血糖控制、血脂、体重和炎症指标。
- 可考虑将每日增加纤维15 g或达到35 g作为降低早死风险的合理目标。
- 纤维摄入的获益不限于特定纤维类型或糖尿病类型。
局限性
- 缺乏非欧洲国家的前瞻性队列数据。
- 缺乏长期(12个月或以上)增加纤维摄入的对照试验。
- 所有试验分析存在高度异质性。
- 影响结果的变量包括基线纤维摄入、试验所在全球区域及糖尿病类型以外的纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibre is promoted as part of a healthy dietary pattern and in diabetes management. We have considered the role of high-fibre diets on mortality and increasing fibre intake on glycaemic control and other cardiometabolic risk factors of adults with prediabetes or diabetes. METHODS AND FINDINGS: We conducted a systematic review of published literature to identify prospective studies or controlled trials that have examined the effects of a higher fibre intake without additional dietary or other lifestyle modification in adults with prediabetes, gestational diabetes, type 1 diabetes, and type 2 diabetes. Meta-analyses were undertaken to determine the effects of higher fibre intake on all-cause and cardiovascular mortality and increasing fibre intake on glycaemic control and a range of cardiometabolic risk factors. For trials, meta regression analyses identified further variables that influenced the pooled findings. Dose response testing was undertaken; Grading of Recommendations Assessment, Development and Evaluation (GRADE) protocols were followed to assess the quality of evidence. Two multicountry cohorts of 8,300 adults with type 1 or type 2 diabetes followed on average for 8.8 years and 42 trials including 1,789 adults with prediabetes, type 1, or type 2 diabetes were identified. Prospective cohort data indicate an absolute reduction of 14 fewer deaths (95% confidence interval (CI) 4-19) per 1,000 participants over the study duration, when comparing a daily dietary fibre intake of 35 g with the average intake of 19 g, with a clear dose response relationship apparent. Increased fibre intakes reduced glycated haemoglobin (HbA1c; mean difference [MD] -2.00 mmol/mol, 95% CI -3.30 to -0.71 from 33 trials), fasting plasma glucose (MD -0.56 mmol/L, 95% CI -0.73 to -0.38 from 34 trials), insulin (standardised mean difference [SMD] -2.03, 95% CI -2.92 to -1.13 from 19 trials), homeostatic model assessment of insulin resistance (HOMA IR; MD -1.24 mg/dL, 95% CI -1.72 to -0.76 from 9 trials), total cholesterol (MD -0.34 mmol/L, 95% CI -0.46 to -0.22 from 27 trials), low-density lipoprotein (LDL) cholesterol (MD -0.17 mmol/L, 95% CI -0.27 to -0.08 from 21 trials), triglycerides (MD -0.16 mmol/L, 95% CI -0.23 to -0.09 from 28 trials), body weight (MD -0.56 kg, 95% CI -0.98 to -0.13 from 18 trials), Body Mass Index (BMI; MD -0.36, 95% CI -0·55 to -0·16 from 14 trials), and C-reactive protein (SMD -2.80, 95% CI -4.52 to -1.09 from 7 trials) when compared with lower fibre diets. All trial analyses were subject to high heterogeneity. Key variables beyond increasing fibre intake were the fibre intake at baseline, the global region where the trials were conducted, and participant inclusion criteria other than diabetes type. Potential limitations were the lack of prospective cohort data in non-European countries and the lack of long-term (12 months or greater) controlled trials of increasing fibre intakes in adults with diabetes. CONCLUSIONS: Higher-fibre diets are an important component of diabetes management, resulting in improvements in measures of glycaemic control, blood lipids, body weight, and inflammation, as well as a reduction in premature mortality. These benefits were not confined to any fibre type or to any type of diabetes and were apparent across the range of intakes, although greater improvements in glycaemic control were observed for those moving from low to moderate or high intakes. Based on these findings, increasing daily fibre intake by 15 g or to 35 g might be a reasonable target that would be expected to reduce risk of premature mortality in adults with diabetes.
引用
- Reynolds AN, Akerman AP, Mann J, et al. Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med. 2020. PMID: 32142510. doi:10.1371/journal.pmed.1003053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。